Sonnet BioTherapeutics shareholders approve proposed business merger with Hyperliquid Strategies Inc.
-
最新报道：According to a press release from Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), Sonnet announced that its shareholders approved, at a special meeting, a proposed business merger with Hyperliquid Strategies Inc. (HSI) and Rorschach I LLC. The final vote will be filed with the U.S. Securities and Exchange Commission (SEC) on Form 8-K. Sonnet is an oncology-focused biotechnology company with a proprietary biologics innovation platform, FHAB (Fully Human Albumin Binding). This technology utilizes human serum albumin (HSA) to deliver drugs to target tissues, aiming to improve the safety and efficacy of immunomodulatory biologics. Under the proposed business merger transaction, HSI's Form S-4 registration statement, which includes a proxy statement for Sonnet shareholders, became effective on October 27 and will also constitute HSI's prospectus. Upon completion of the proposed business merger, HSI's securities are expected to be listed on Nasdaq.
下一篇
The decline in Bitcoin's implied volatility indicates a reduction in market panic.
- According to a tweet from Coin Bureau, Bitcoin prices have fallen to levels seen in Novemb...
24小时热点
热点专题
413209